Huons Presents Research on Crohn's Fibrosis Drug
The company unveiled preclinical results for its oral TG2 inhibitor at the 2026 UEG Week congress.
Updated on Oct. 20, 2026 in Healthcare
Live Poll
Do you trust that new medical treatments are effectively addressing the root causes of chronic diseases?
Huons has shared new preclinical research for HUC1A-626, an oral drug candidate designed to treat intestinal fibrosis in Crohn's disease patients. The findings were presented during the UEG Week 2026 congress in Barcelona.
Why it matters
Current therapeutic options for Crohn's disease primarily target inflammation, leaving a critical gap for treatments that can reverse or manage established fibrotic tissue. HUC1A-626 offers a potential new approach by inhibiting the TG2 enzyme to reduce tissue stiffening.
Intestinal fibrosis impacts approximately 50% of Crohn's disease patients. Preclinical experiments demonstrated that HUC1A-626 successfully inhibited TG2 activity in human colonic fibroblasts and reduced collagen levels in animal models.
The players
Huons
Huons is a South Korean pharmaceutical company that focuses on the development of specialized medical treatments and drug candidates.
The details
The drug candidate works by inhibiting the TG2 enzyme, which prevents the abnormal cross-linking of extracellular matrix proteins that leads to intestinal hardening. By acting locally in the intestinal tract, HUC1A-626 aims to reduce fibrotic lesions, and Huons now intends to accelerate the drug's development pipeline.
Timeline
October 17 to 20, 2026: UEG Week 2026 congress held in Barcelona.
October 20, 2026: Huons announced the preclinical research findings.
Market Landscape
The presentation at the UEG Week 2026 congress highlights how specialized pharmaceutical development is evolving to meet unmet needs in gastroenterology. Huons is positioning itself to compete in the growing market for fibrotic disease treatments, which has historically been underserved by traditional anti-inflammatory therapies.
For patients living with Crohn's disease, this research represents a potential future shift toward treatments that address the structural complications of the condition. While the drug is not yet available, successful clinical progression could eventually offer an alternative to current standards that only manage inflammation.
The takeaway
This development highlights the ongoing shift toward precision therapies that target specific enzymatic pathways involved in tissue damage. Future clinical milestones will determine if this approach can successfully translate from animal models to effective human treatment.
Further reading
Explore the latest developments in the Healthcare sector.
Live Poll
Do you trust that new medical treatments are effectively addressing the root causes of chronic diseases?
